4/AAccepted Aug 28, 8:18 PM ET
Monopar (MNPR) Director Kim Tsuchimoto Sells 4,090 Shares, Exercises Options
Accepted (ET)
8:18 PM
Aug 28, 2026
Filed
Aug 28, 2026
Documents
1
Size
23.6 KB
Summary
Monopar (MNPR) Director Kim Tsuchimoto Sells 4,090 Shares, Exercises Options
What Happened
Kim R. Tsuchimoto, a director of Monopar Therapeutics (MNPR), exercised options to acquire 4,090 shares (2,055 shares at $30.00 and 2,035 shares at $14.00) on August 26, 2026, and sold those 4,090 shares the same day in multiple open‑market transactions. The option exercises required cash payments totaling about $90,140; the subsequent sales generated total gross proceeds of about $455,567. Both the exercises and the sales were effected pursuant to a Rule 10b5‑1 trading plan.
Key Details
- Transaction date: August 26, 2026 (reported in an amended Form 4 filed Aug 28, 2026).
- Option exercises (code M): 2,055 shares @ $30.00 ($61,650) and 2,035 shares @ $14.00 ($28,490). Form also lists corresponding derivative‑conversion entries showing $0.00 (conversion of derivative securities into common shares).
- Open‑market sales (code S): total 4,090 shares across multiple trades; tranche prices range by footnote from about $108.07 to $114.34; total proceeds ≈ $455,567. Weighted‑average prices are reported per tranche (see footnotes F4–F9 for ranges).
- Plan / authorization: Transactions were made under a Rule 10b5‑1 plan executed May 27, 2026 (F1).
- Ownership after transaction: Not specified in the excerpt; footnote F10 references shares held by the Kim R. Tsuchimoto Trust dated Oct 6, 2015.
- Timeliness / filing: This is an amended Form 4. The filer previously submitted a Form 4 (Aug 27) that inadvertently omitted the two option exercises; this amendment adds those exercises (late filing of prior omission).
Context and plain‑language notes
- Transaction codes: M = option exercise/conversion of derivative; S = sale. Here, the insider exercised options and sold the same number of shares on the same day — a common pattern when exercised shares are sold to cover the exercise cost or for liquidity.
- No inference of future company performance should be drawn from routine option exercises and 10b5‑1 plan trades; the filing is corrective (amended) to include previously omitted exercises.